Novo Nordisk A/S buy klostergang
Summary
This prediction ended on 01.10.18 with a price of €40.62. During the runtime of the prediction for Novo Nordisk A/S the price only changed by -0.57%. klostergang has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novo Nordisk A/S | - | - | - | - |
iShares Core DAX® | -5.585% | -6.284% | 8.869% | 8.070% |
iShares Nasdaq 100 | -7.241% | -13.117% | 18.200% | 28.955% |
iShares Nikkei 225® | -8.933% | -10.904% | 2.614% | -1.478% |
iShares S&P 500 | -6.148% | -7.562% | 17.896% | 31.811% |
Comments by klostergang for this prediction
In the thread Novo Nordisk A/S diskutieren
klostergang stimmt der Buy-Einschätzung von mohabbatein zu
klostergang stimmt am 16.10.2017 der Buy-Einschätzung von mohabbatein aber mit dem Kursziel 50€ zu.
Überschrift: Einstiegschance nach negativem Analystenkommentar